The 2025 annual report explicitly discloses CRO/CDMO operations and process platforms including continuous flow and photochemistry.
ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companiesShowing 24 / 471
The 2020 annual report explicitly describes Pudao CRO/CMO/CDMO. The 2025 report confirms wholly owned status and a 2026 CDMO expansion plan.
ChinaFull profile →
The 2024 investor relations record explicitly identifies a CMO/CDMO service business.
ChinaFull profile →
The 2025 annual report discloses pharmaceutical CDMO, customer concentration, and key-product concentration. The website confirms CDMO/API capabilities.
ChinaFull profile →
The 2025 annual report explicitly identifies CMO/CDMO and collaborations with customers including Boehringer Ingelheim, Pfizer, and Meiji.
ChinaFull profile →
AllerGene proposes in vivo-delivered mRNA CAR-T to target mast cells in allergic disease. Its website establishes research intent, but does not establish a named clinical candidate, patient dosing, or validated allergy outcomes. It is distinct from Allogene Therapeutics.
United StatesFull profile →
The 2025 annual report identifies a commercial imrecoxib API CMO/CDMO project generating RMB 52.8043 million in revenue; this is not total group revenue.
ChinaFull profile →
The 2025 annual report attributes revenue to eye-drop production/sales, contract manufacturing, and technical services. The website explicitly describes integrated ophthalmic product design, R&D, and CMO/CDMO.
ChinaFull profile →
The 2025 annual report confirms a steroid CDMO facility at wholly owned Goto Biopharm, using capacity to provide custom research/manufacturing for global pharmaceutical clients.
ChinaFull profile →
Annual reports confirm sequencing-related drug-development solutions for pharmaceutical companies. The current website offers preclinical, translational, organoid drug-sensitivity, and multiomics services. Much business serves academic research; included as diversified with group-level financials.
ChinaFull profile →
The pharmaceutical collaboration page explicitly covers target discovery, biomarker research, clinical trial assay (CTA) development, and companion diagnostics. Distinct from diagnostic product sales; included as diversified, with group financials.
ChinaFull profile →
The latest interim report explicitly describes CRO collaborations with innovative pharmaceutical companies and new contracts, separately disclosing research services/CRO. Clinical specialty testing remains the main business; included as diversified with group-level financials.
ChinaFull profile →
The CRO page explicitly offers third-party clinical trial laboratory testing for pharmaceutical companies under drug GCP and ISO 15189, alongside diagnostics and IVD sales. Included as diversified with group financials.
ChinaFull profile →
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
ChinaFull profile →
Frontage Laboratories offers Analytical development, GMP release, bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.
United States / ChinaFull profile →
Intellia presents CRISPR gene-editing science, clinical programs, and scientific publications on its official website. Its gene-editing work belongs in this broader in vivo engineering field; it should not be labeled as equivalent to in vivo CAR-T.
United StatesFull profile →
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
United StatesFull profile →
AbbVie completed its Capstan acquisition in August 2025. CPTX2309 uses targeted LNP in vivo CAR-T technology; the sponsor lists NCT06917742 as a recruiting Phase 1 study in healthy volunteers, rheumatoid arthritis, and SLE. Registration does not establish efficacy.
United StatesFull profile →
Labcorp offers Bioanalytical testing and biomarker quantitation. Services should be matched to the intended study and assay requirements.
United States / United Kingdom / ChinaFull profile →
Resolian offers Bioanalysis, DMPK and biomarker testing. Services should be matched to the intended study and assay requirements.
United States / United Kingdom / Germany / China / 澳大利亚Full profile →
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
Tessera develops Gene Writing and RNA delivery technologies for genomic changes and targeted in vivo applications. Its November 2026 ASH announcement concerns preclinical studies, including CAR-T generation in nonhuman primates.
Tune develops TEMPO epigenetic regulation to activate or silence gene expression without cutting or changing the DNA sequence. Epigenetic modulation should be distinguished from sequence editing and permanent DNA insertion.
Sana develops CD8-targeted fusosome in vivo CAR-T, including SG293 and BCMA-directed SG227. Its August 2026 update describes SG293 clinical-start preparations and surrogate nonhuman-primate data, with SG227 clinical entry projected as early as 2027. Human dosing was not verified in this review.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.